mednow semaglutide greenwood village Semaglutide-mvanhaasteren.nl Semaglutide Medical Weight Loss Program

FLOW trial findings show semaglutide is associated with sustained improvements in quality of life in chronic kidney disease (CKD).

Todd Sohn, Strategas ETF & Technical Strategist, also joins the conversation.

Graphical Abstract Created in BioRender

Tiny portions

Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer.

Researchers at the Lunenfeld-Tanenbaum Research Institute, part of Sinai Health, have discovered a gut-brain-immune network and posit a new gut-brain glucagon-like peptide 1 (GLP-1R) that controls inflammation across the body, a discovery which holds promise for understanding and treating metabolic diseases